Table 2 Current CD30-Directed CAR-T Cell Clinical Trials for Relapsed/Refractory CD30+ Lymphoma
From: Challenges of driving CD30-directed CAR-T cells to the clinic
Clinicaltrials.gov Identifier | Conditioning Regimen | Doses | Included Ages | Estimated Enrollment | Location |
|---|---|---|---|---|---|
NCT02259556a | Cy/flu | Not specified (dose escalation) | 16–80 years | 30 | Chinese PLA General Hospital |
NCT02690545 | Flu/benda | 1 × 108 cells/m2, 2 × 108 cells/m2 | 3 years and older | 34 | University of North Carolina |
NCT02917083 | Cy/flu (if post ASCT, T-cell infusion at least 14 days after transplant) | 2 × 107 cells/m2, 1 × 108 cells/m2, 2 × 108 cells/m2 | 12–75 years | 18 | Baylor College of Medicine |
NCT03049449 | Cy/flu | 0.3 × 106 cells/kg up to maximum dose of 18 × 106 cells/kg | 18–73 years | 76 | National Cancer Institute |
NCT03383965 | Not specified | Not specified (dose escalation) | 2–80 years | 20 | Weifang People’s Hospital |
NCT02663297 | ASCT | 2 × 107 cells/m2, 1 × 108 cells/m2, 2 × 108 cells/m2 | 3 years and older | 18 | University of North Carolina |
NCT02958410 | Not specified | Not specified (dose escalation) | 14 to 75 years | 45 | Southwest Hospital, China |